Navigation Links
Oramed Pharmaceuticals Announces Filing of Two Registration Statements
Date:1/11/2010

JERUSALEM, Israel, January 11 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB), a developer of alternative drug delivery systems, today announced that it has filed two registration statements on Form S-1 with the Securities and Exchange Commission.

One registration statement relates to a proposed public offering by Oramed of 24 million shares of common stock and warrants to purchase 12 million shares of common stock, as well as warrants to purchase up to approximately 2.5 million shares of common stock issuable to the placement agent of the offering.

This offering shall be made only by means of a prospectus. Copies of the preliminary prospectus, when available, may be obtained from Oramed. The registration statement may be accessed through the SEC's website at http://www.sec.gov.

Oramed expects to use the net proceeds from the offering to fund its planned research and development activities, as well as some other general and administrative costs.

The second filing is a shelf registration statement relating to a resale offering by certain Oramed stockholders of approximately 8.5 million shares of common stock and approximately 4.8 million shares of common stock issuable upon the exercise of warrants held by stockholders of Oramed who purchased such securities in private placement transactions.

This press release is made in accordance with Rule 135 under the Securities Act. Registration statements relating to these securities have been filed with the Securities and Exchange Commission but have not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the applicable registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.

For more information, please visit http://www.oramed.com

Forward-looking statements

Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Oramed, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and Oramed's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to Oramed's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of Oramed to differ materially from those expressed or implied in such forward looking statements. Oramed undertakes no obligation to update or revise any forward-looking statements.

    Company Contact:

    Oramed Pharmaceuticals
    Tara Horn
    Cell: +972-54-334-318
    Office: +972-2-566-0001
    Email: tara@oramed.com

SOURCE Oramed Pharmaceuticals Inc.


'/>"/>
SOURCE Oramed Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Oramed Pharmaceuticals was Chosen to Present Results of a GLP-1 Analog Oral Administration Study at the Diabetes Technology Societys Ninth Annual Meeting (November 5-7, 2009; San Francisco, CA)
2. Orameds Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the 2009 British Pharmaceutical Conference in Manchester, England
3. Oramed Pharmaceuticals to Present at the 8th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2009
4. Oramed Pharmaceuticals Announces Launch of Phase 2B Clinical Trials in South Africa of its Oral Insulin Capsule
5. Oramed Pharmaceuticals to Present Oral Insulin Phase 2A Trial Results at the Upcoming Annual Meeting of the ADA (June 5-9, New Orleans, LA)
6. Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository
7. Oramed Pharmaceuticals Chosen to Present Results of GLP-1 Analog Enteral Administration Study at the Diabetes Technology Societys Eighth Annual Meeting (November 13-15, 2008; Bethesda, Maryland)
8. Oramed Pharmaceuticals Launches Phase 1A Trials of its Insulin Suppository
9. /K I L L K I L L K I L L -- Oramed Pharmaceuticals Inc./
10. Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
11. Oramed Pharmaceuticals Launches GLP1-Analog Program, Based on its Proprietary Drug Delivery Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Feb. 23, 2017 Visiomed, the French ... since 1997, is changing the landscape of healthcare ... patients with pro-active, custom-made solutions. Recognizing the rising ... and affordable healthcare without walls, Visiomed has launched ... developed with healthcare professionals that is empowering the ...
(Date:2/23/2017)... SEOUL , Südkorea, 23. Februar 2017 ... LED für Sterilisationsaufgaben vorgestellt. Die Sterilisationsleistung beträgt das 1,5-fache ... kurzwellige ultraviolette Strahlung im Bereich zwischen 200 und 280 nm ... Ausbreitung von Bakterien, indem es ihre DNA zerstört. Das ... 280 nm. ...
(Date:2/23/2017)... REDWOOD CITY, Calif., Feb. 23, 2017 Nevro Corp. ... innovative evidence-based solutions for the treatment of chronic pain, today ... ended December 31, 2016. 2016 Accomplishment & ... the full year 2016, an increase of 228% as reported, ... million for 2016, an increase of 612% over the prior ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... , ... Current Meditation , a new meditation concept ... U.S. starting this spring. Current Meditation focuses on “meditation for the modern world,” ... will be the first meditation concept in the U.S. offering franchising opportunities, setting ...
(Date:2/23/2017)... ... (PRWEB) ... opportunity for the nation to come together to combine its ... – with its favorite fruit – apples! To celebrate National ... to join the “Apple Madness” bracket tournament – a five-week, ...
(Date:2/23/2017)... ... February 23, 2017 , ... Curemark, LLC announced today that the Blüm ... in children aged 3-8 with Autism, is now enrolling at three new sites. These ... the United States. , “There are currently no approved drugs that address the ...
(Date:2/23/2017)... ... February 23, 2017 , ... Carlos Gutierrez has lived ... continued to spiritually evolve, which is the purpose of everyone in this universe. As ... ” (published by Balboa Press) attempts to guide readers to expand one’s spiritual life. ...
(Date:2/22/2017)... ... February 22, 2017 , ... Gevir, a New Zealand-based company that ... its products are coming soon to Amazon.com, the world’s largest online retailer. ... means to develop an effective natural treatment for Shelley’s Multiple Sclerosis, which she’d been ...
Breaking Medicine News(10 mins):